Source: Drug Genius

Terns Pharmaceuticals: TFF Pharmaceuticals Announces Completion of Dosing for Voriconazole Inhalation Powder Phase 1 Clinical Trial

Phase 1 repeated dosing of Voriconazole Inhalation Powder of up to 80 mg/dose in healthy subjects for direct-to-lung delivery of voriconazole for Invasive Pulmonary Aspergillosis AUSTIN, Texas-(BUSINESS WIRE)-TFF Pharmaceuticals, Inc. (NASDAQ: TFFP), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today [...]The post TFF Pharmaceuticals Announces Completion of Dosing for Voriconazole Inhalation Powder Phase 1 Clinical Trial appeared first on Drug Genius.

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Est. Annual Revenue
Est. Employees
Senthil Sundaram's photo - CEO of Terns

CEO

Senthil Sundaram

CEO Approval Rating

90/100

Terns is a biopharmaceutical company that develops and commercializes therapeutics for the treatment of cancer and liver diseases. Read more